Antibiotic Resistance

Study finds reduction in antibiotic overprescribing to limit growth of drug market

Published in Drug Week, December 3rd, 2004

Decision Resources, Inc., has found that pressure from expert panels, payers, and public health officials to reduce antibiotic overprescribing will limit growth of the acute exacerbations of chronic bronchitis (AECB) drug market over the next decade.

"AECB is currently overtreated with antibiotics, and experts suggest that a subset of patients with minor symptoms probably do not require antibiotic therapy," said Aarti Raja, PhD, analyst at Decision Resources. "However, because AECB patients often have multiple other medical problems, primary care physicians tend to err on the side of caution and prescribe antibiotics-often the 'latest and greatest.'"

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2004-12-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry